The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORγ modulators last year in February and March. While most clinical RORγ modulators have discontinued development after reaching Ph. II, BI 730357’s Ph. II trial appears [...]
< 1 minute read
Sep. 18, 2021
BI 730357: An Oral RORy Nuclear Receptor Antagonist
BI 730357
oral RORy nuclear receptor antagonist on-going Ph. II for psoriasis (QD dosing) 50k cmpd high-conc. frag. screen + scaff. hop ACS Med. Chem. Lett., Jan. 5, 2021 Boehringer Ingelheim, Ridgefield, CT
Loading...
